Nomograms predicting recurrence in patients with triple negative breast cancer based on ultrasound and clinicopathological features
- PMID: 35819909
- PMCID: PMC9815727
- DOI: 10.1259/bjr.20220305
Nomograms predicting recurrence in patients with triple negative breast cancer based on ultrasound and clinicopathological features
Abstract
Objectives: The clinicopathological and ultrasound features associated with recurrence in patients with triple negative breast cancer (TNBC) were used to develop a nomogram to predict the prognosis of TNBC.
Methods: Clinicopathological data of 300 patients with TNBC treated between July 2012 and September 2014 were retrospectively reviewed. The endpoint was progression-free survival (PFS). Prognostic factors were screened by multivariate COX regression to develop nomograms. The C-index and calibration curves were used to evaluate the predictive accuracy and discriminatory ability of nomograms.
Results: Of 300 patients with TNBC followed-up for 5 years, 80 (26.7%) had PFS events. Five informative prognostic factors (large size, vertical orientation, posterior acoustic enhancement, lymph node involvement, and high pathological stage) were screened and used to construct a nomogram for PFS. The C-index of the PFS nomogram was 0.88 (p < 0.01, 95% confidence interval, 0.85-0.90), indicating good predictive accuracy.
Conclusions: We developed and validated a nomogram for predicting PFS in TNBC. Vertical orientation and posterior acoustic enhancement in ultrasound images of TNBC were associated with worse outcomes.
Advances in knowledge: Patients with TNBC have a very poor prognosis and patients have a high risk of recurrence, and our study developed a nomogram based on ultrasound and clinicopathological features for TNBC patients to improve the accuracy of individualized prediction of recurrence and provide help for clinical treatment.
Conflict of interest statement
Figures




Similar articles
-
Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.Eur Radiol. 2022 Oct;32(10):6575-6587. doi: 10.1007/s00330-022-08910-4. Epub 2022 Jun 27. Eur Radiol. 2022. PMID: 35759017 Free PMC article.
-
Radiomics features on ultrasound imaging for the prediction of disease-free survival in triple negative breast cancer: a multi-institutional study.Br J Radiol. 2021 Oct 1;94(1126):20210188. doi: 10.1259/bjr.20210188. Epub 2021 Sep 3. Br J Radiol. 2021. PMID: 34478336 Free PMC article.
-
Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients.Cancer Manag Res. 2019 Dec 30;11:10827-10839. doi: 10.2147/CMAR.S234926. eCollection 2019. Cancer Manag Res. 2019. PMID: 31920392 Free PMC article.
-
Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer.Future Oncol. 2021 Dec;17(36):5077-5091. doi: 10.2217/fon-2021-0677. Epub 2021 Oct 27. Future Oncol. 2021. PMID: 34704816
-
Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.BMC Cancer. 2019 Jun 6;19(1):541. doi: 10.1186/s12885-019-5703-4. BMC Cancer. 2019. PMID: 31170946 Free PMC article.
Cited by
-
Prediction of disease-free survival using strain elastography and diffuse optical tomography in patients with T1 breast cancer: a 10-year follow-up study.BMC Cancer. 2024 Aug 27;24(1):1057. doi: 10.1186/s12885-024-12844-z. BMC Cancer. 2024. PMID: 39192199 Free PMC article.
-
Machine learning-based ultrasound radiomics for predicting risk of recurrence in breast cancer.Front Oncol. 2025 May 12;15:1542643. doi: 10.3389/fonc.2025.1542643. eCollection 2025. Front Oncol. 2025. PMID: 40421082 Free PMC article.
References
-
- Siegel RL MK, Jemal A. Cancer statistics. CA Cancer J Clin 2018; 68(1). - PubMed
-
- Kim Y-I, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung J-K, et al. . Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2017; 44: 1787–95. doi: 10.1007/s00259-017-3748-7 - DOI - PubMed